| Drew C Fuller, MD | |
|
7310 Ritchie Hwy Ste 516, Glen Burnie, MD 21061-3099 | |
| (443) 221-2222 | |
| Not Available |
| Full Name | Drew C Fuller |
|---|---|
| Gender | Male |
| Speciality | Addiction Medicine |
| Experience | 29 Years |
| Location | 7310 Ritchie Hwy Ste 516, Glen Burnie, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801808209 | NPI | - | NPPES |
| 511505100 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083A0300X | Preventive Medicine - Addiction Medicine | D53298 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brightwell Health Llc | 8224437397 | 5 |
News Archive
The American Mosquito Control Association's annual National Mosquito Control Awareness Week aims to educate about the significance of mosquitoes and the importance of eliminating them. Amy Lawhorne, vice president and brand leader at Mosquito Squad, the largest and most experienced home and commercial mosquito control firm in the country, is putting mosquitoes on notice.
BeaconEquity.com announces an investment report featuring Intellipharmaceutics International Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The study of tobacco has been the life-long focus of his research and now, Peter Shields, MD, deputy director of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, has led the effort to edit a special-edition of Cancer Epidemiology, Biomarkers & Prevention (CEBP) dedicated to best research practices in tobacco science from researchers the world over.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.
Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.
› Verified 6 days ago
| Entity Name | Emergency Medicine Associates Pa Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134117393 PECOS PAC ID: 8022914522 Enrollment ID: O20040126000955 |
News Archive
The American Mosquito Control Association's annual National Mosquito Control Awareness Week aims to educate about the significance of mosquitoes and the importance of eliminating them. Amy Lawhorne, vice president and brand leader at Mosquito Squad, the largest and most experienced home and commercial mosquito control firm in the country, is putting mosquitoes on notice.
BeaconEquity.com announces an investment report featuring Intellipharmaceutics International Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The study of tobacco has been the life-long focus of his research and now, Peter Shields, MD, deputy director of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, has led the effort to edit a special-edition of Cancer Epidemiology, Biomarkers & Prevention (CEBP) dedicated to best research practices in tobacco science from researchers the world over.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.
Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.
› Verified 6 days ago
| Entity Name | Calvert County Health Department |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609137918 PECOS PAC ID: 7214188366 Enrollment ID: O20121119000361 |
News Archive
The American Mosquito Control Association's annual National Mosquito Control Awareness Week aims to educate about the significance of mosquitoes and the importance of eliminating them. Amy Lawhorne, vice president and brand leader at Mosquito Squad, the largest and most experienced home and commercial mosquito control firm in the country, is putting mosquitoes on notice.
BeaconEquity.com announces an investment report featuring Intellipharmaceutics International Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The study of tobacco has been the life-long focus of his research and now, Peter Shields, MD, deputy director of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, has led the effort to edit a special-edition of Cancer Epidemiology, Biomarkers & Prevention (CEBP) dedicated to best research practices in tobacco science from researchers the world over.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.
Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.
› Verified 6 days ago
| Entity Name | Brightwell Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215515408 PECOS PAC ID: 8224437397 Enrollment ID: O20210521000216 |
News Archive
The American Mosquito Control Association's annual National Mosquito Control Awareness Week aims to educate about the significance of mosquitoes and the importance of eliminating them. Amy Lawhorne, vice president and brand leader at Mosquito Squad, the largest and most experienced home and commercial mosquito control firm in the country, is putting mosquitoes on notice.
BeaconEquity.com announces an investment report featuring Intellipharmaceutics International Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The study of tobacco has been the life-long focus of his research and now, Peter Shields, MD, deputy director of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, has led the effort to edit a special-edition of Cancer Epidemiology, Biomarkers & Prevention (CEBP) dedicated to best research practices in tobacco science from researchers the world over.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.
Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Drew C Fuller, MD 7310 Ritchie Hwy Ste 516, Glen Burnie, MD 21061-3099 Ph: () - | Drew C Fuller, MD 7310 Ritchie Hwy Ste 516, Glen Burnie, MD 21061-3099 Ph: (443) 221-2222 |
News Archive
The American Mosquito Control Association's annual National Mosquito Control Awareness Week aims to educate about the significance of mosquitoes and the importance of eliminating them. Amy Lawhorne, vice president and brand leader at Mosquito Squad, the largest and most experienced home and commercial mosquito control firm in the country, is putting mosquitoes on notice.
BeaconEquity.com announces an investment report featuring Intellipharmaceutics International Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The study of tobacco has been the life-long focus of his research and now, Peter Shields, MD, deputy director of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, has led the effort to edit a special-edition of Cancer Epidemiology, Biomarkers & Prevention (CEBP) dedicated to best research practices in tobacco science from researchers the world over.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.
Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.
› Verified 6 days ago
Pratiksha Vishal Patel Vaghela, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 811 Cromwell Park Dr, Suite 104, Glen Burnie, MD 21061 Phone: 859-619-6648 |